31-45 of 305
Double-Class Refractory CLL in Community Practice: Current and Future Management
CME/CEDouble-Class Refractory CLL in Community Practice: Current and Future Management
John C. Byrd, MD
William Mencia, MD, FACEHP
William Wierda, MD, PhD
Matthew S. Davids, MD, MMSc
Progress in Breast Cancer Care: Translating SABCS Data Into Practice
CME/CEProgress in Breast Cancer Care: Translating SABCS Data Into Practice
Charles E. Geyer Jr., MD, FACP
Komal Jhaveri, MD, FACP
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
CME/CEAdvancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Cristina Rodriguez, MD
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
CME/CEFrom Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
María-Victoria Mateos, MD, PhD
Luciano Costa, M.D., Ph.D.
- MinuteCE®
The New Era of RAS Targeting: Mechanisms, Evidence, and Clinical Integration of ON-State Inhibitors
Kathryn Arbour
Eileen M. O'Reilly, MD
- advertisement
Kathryn Arbour
Eileen M. O'Reilly, MD
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
MinuteCE®Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
Kathryn Arbour
Eileen M. O'Reilly, MD
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
MinuteCE®Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
Kathryn Arbour
Eileen M. O'Reilly, MD
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
MinuteCE®Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
Kathryn Arbour
Eileen M. O'Reilly, MD
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
MinuteCE®NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
Kathryn Arbour
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors
MinuteCE®Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors
Eileen M. O'Reilly, MD
- advertisement
Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
MinuteCE®Novel RAS-Targeted Therapy: Prevention, Monitoring, and Mitigation of Adverse Events
Eileen M. O'Reilly, MD
Kathryn Arbour
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
MinuteCE®RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
Kathryn Arbour
Eileen M. O'Reilly, MD
Frontline Insights: Emerging Therapeutic Strategies in HNSCC
CME/CEFrontline Insights: Emerging Therapeutic Strategies in HNSCC
Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Christophe Le Tourneau, MD, PhD
